Welcome to OpenDEL™ Community A central hub to connect with global DEL professionals, access the latest industry insights and product updates, and collaborate to accelerate drug discovery. Learn More
DEL-Related Publications 25 May 2026 Peptides as Programmable Molecular Scaffolds: From Chemical Synthesis and Engineering to Translational Medicine Shaoren Yuan , Baljit Kaur , Natalie Fuchs , Sungwoo Cho , Ashraf Abdo , Moustafa Gabr RSC Chemical Biology DOI: 10.1039/d6cb00117c Abstract Peptides have evolved from naturally occurring ligands and classical hormones into a versatile and engineerable class of functional molecules. This review provides a comprehensive overview of the technological advances that collectively enable programmable peptide engineering across the entire discovery-to-development pipeline. We first discuss innovations in automated flow synthesis, chemoselective ligation, noncanonical residue incorporation, backbone editing, conformational constraint, and late-stage functionalization that have transformed peptide chemistry from linear sequence assembly into a modular engineering platform. We then examine modern discovery approaches including phage display, mRNA display with the RaPID system, and DNA-encoded chemical libraries, alongwith computational and AI-enabled design strategies that accelerate hit identification and multi parameter optimization. Biophysical characterization techniques, cellular target engagement assays, and emerging delivery strategies are also reviewed as critical tools for bridging biochemical potency with intracellular activity. Finally, we discuss the translational barriers facing peptide therapeutics and the engineering strategies that have enabled successful clinical applications. Together, these advances establish a new era which peptides are no longer viewed as inherently labile biomolecules but as chemically programmable scaffolds whose structures and functions can be precisely engineered. Learn More DEL-Related Publications 24 May 2026 A Mild and DNA-Compatible Cyclization Strategy for the Construction of [1,2,4]Triazolo[1,5-a]pyridine Scaffolds Zhaobing Ding, Feifei Li, Jun Lu, Bing Qi Organic Letters DOI: 10.1021/acs.orglett.6c01786 Abstract Here, we report a mild and DNA-compatible cyclization strategy for the construction of [1,2,4]triazolo[1,5-a]pyridine scaffolds that is well suited for DNA-encoded library (DEL) construction. This reaction proceeds via cyclocondensation of aldehydes with 1,2-diaminopyridinium salt substrates under mild and simple conditions. This method enables the rapid and efficient construction of a series of DNA-encoded libraries containing compounds with a potentially biologically active [1,2,4]triazolo[1,5-a]pyridine scaffold. Learn More DEL-Related Publications 19 May 2026 Efficient 96-Well Plate Conjugation of Unnatural Amino Acid Building Blocks to DNA for DNA-Encoded Library Applications. Peter Blakskjær,Tobias N Hansen,Lars K Petersen,Frank A Sløk,Nils J V Hansen Bioconjugate Chemistry DOI: 10.1021/acs.bioconjchem.6c00010 Abstract Herein, we describe a robust 96-well plate workflow for high-throughput synthesis of building block–oligonucleotide conjugates for the synthesis of DNA-encoded libraries. Building blocks are Boc- and pNs-protected aminoesters, and the method allows consecutive ligation of codon oligonucleotides, ester hydrolysis, and conjugation in one pot. Results from using the two protection group strategies are discussed. Building blocks are conjugated using DMTMM to codon-specific PEG12-amino-modified oligonucleotides made from ligation. Conjugates are purified by HPLC, and all manipulations including precipitation of DNA are done in 96-well plates, reducing hands-on time. Learn More DEL Insights 9 May 2026 DEL Insight | Hermes: Large DEL Datasets Train Generalizable Protein-Ligand Binding Prediction Models Research Background Protein–ligand interaction (PLI) prediction is a central task in computational drug discovery. Existing public affinity datasets such as BindingDB and ChEMBL are highly heterogeneous in origin, having been aggregated from thousands of laboratories using many different experimental protocols. As a result, they suffer from systematic bias and substantial standardization challenges, which in turn limit model generalization. In contrast, DNA-encoded library (DEL) technology enables ultrahigh-throughput screening of billions of compounds under unified experimental protocols, providing a new source of large-scale, high-quality training data for PLI modeling. Model Architecture Hermes adopts a lightweight Transformer-based architecture. Its main components are: Pretrained sequence encoders: ESM2-150M for protein sequences, with only the final four layers trainable, and ChemBERTa-77M-MTR for ligand SMILES strings, with all parameters trainable. Joint cross-attention module: alternating self-attention blocks, which process protein and ligand sequences separately, and cross-attention blocks, which enable information exchange between protein and ligand tokens. Attention pooling layers: differentiable pooling functions that learn importance scores and aggregate variable-length sequences into fixed-dimensional vectors. Prediction head: a multilayer perceptron (MLP) that outputs a binding probability. For final inference, the authors used an ensemble of nine checkpoints trained with different hyperparameter settings and training-sampling strategies, and averaged their predictions. Figure 1. Hermes architecture diagram. Training Data Hermes was trained on DEL screening data generated from the Kin0 chemical library, which contains 6.5 million members and was constructed as a three-cycle library using 38 cores connected to 384 and 446 building blocks. The dataset covers 239 unique protein targets, approximately two-thirds of which are kinases. Labels were generated through a binarized hit-calling procedure based on enrichment relative to control screens, including DEL-only, bead-only/no-target, and proprietary controls. To manage class imbalance, the training procedure capped the number of positive samples per protein target, retained the highest-enrichment hits, and paired each positive example with a fixed number of negatives, drawn from both random negatives and hard negatives. Table 1. Training and evaluation dataset statistics. Model Evaluation Hermes was evaluated on four benchmark datasets designed to test different forms of generalization: 1. DEL Protein Split: 164 protein targets not seen during training, screened against the same Kin0 library. This benchmark tests cold-target generalization. 2. DEL Chemical Library Split (STRELKA): 59 protein targets seen in training, but screened against a different 1-million-member benzimidazole library (AMA020). This benchmark tests cold-ligand generalization. 3. Public Binders/Decoys: 403 protein targets, with positives from Papyrus++ and negatives from GuacaMol property-matched synthetic decoys. This benchmark evaluates generalization to external public binding data. 4. MF-PCBA: 26 protein targets from PubChem BioAssay high-throughput screening data, where confirmed dose-response actives are positives and primary-screen inactives are negatives. This benchmark tests performance on heterogeneous public screening data. The authors compared Hermes against two baselines: Boltz-2, a state-of-the-art structure-based deep learning model built on an AlphaFold3-like architecture. XGBoost, using concatenated ESM2-650M CLS embeddings and ECFP4 fingerprints as features. Table 2. Hermes vs benchmarks per-protein AUROC comparison. Key Findings The results show clear variation across benchmarks, but several important patterns emerge: On DEL Protein Split, both Hermes and the XGBoost baseline outperform Boltz-2, suggesting that DEL-derived training data contains strong information value when the assay system is consistent. On DEL Chemical Library Split, all models perform more weakly, indicating that this benchmark is difficult for cold-ligand generalization. On MF-PCBA, Boltz-2 substantially outperforms Hermes, although part of this benchmark may overlap with Boltz-2’s training data. On Public Binders/Decoys, Hermes clearly outperforms XGBoost, demonstrating stronger generalization to genuinely novel chemical space. The paper also reports that Hermes performs better on kinase targets than on non-kinases in most benchmarks, which is consistent with the kinase-enriched composition of the training set. This suggests that targeted DEL data generation can improve generalization within a protein family. Computational Efficiency Table 3. Inference speed comparison. Hermes is designed for efficient inference. After correcting for hardware differences, the authors estimate that Hermes is approximately 500–700 times faster than Boltz-2. Its sequence-only design allows protein embeddings to be cached, making it well suited for billion-scale virtual screening campaigns. Discussion and Conclusions This study shows that a model trained exclusively on DEL screening data can learn transferable representations of protein–ligand interactions. Without ever being trained on traditional affinity measurements, Hermes generalizes to unseen protein targets, unseen chemical scaffolds, and external datasets derived from different experimental systems. This provides a strong proof of concept for the use of DEL data in PLI modeling. At the same time, the study identifies several limitations. First, the kinase-heavy training distribution leads to weaker performance on non-kinase proteins. Second, binary label binarization likely restricts model expressiveness. Third, performance on data similar to the training set still appears to be influenced by memorization effects. Future work may benefit from incorporating structure-prediction outputs, modeling continuous enrichment scores instead of binary labels, and improving sampling strategies to better support generalization to unseen protein families. Overall, as DEL technology continues to mature and generate data at a faster pace than public affinity databases, DEL-trained models such as Hermes are likely to become an important methodology for the next generation of PLI prediction Reference Kleinsasser M, Halverson B J , Kraft E ,et al.Hermes: Large DEL Datasets Train Generalizable Protein-Ligand Binding Prediction Models[J]. 2026. Learn More DEL-Related Publications 7 May 2026 An RNA-Focused DNA-Encoded Library Platform for Discovering Ligands of Pathogenic r(G4C2)exp RNA Xueyi Yang, Amirhossein Taghavi, Yoshihiro Akahori, Martina Pedrini, Takahiro Ishii, Matthew D. Disney ACS Chemical Biology DOI: 10.1021/acschembio.6c00337 Abstract Disease-associated RNAs are increasingly recognized as promising therapeutic targets for small-molecule intervention. While DNA-encoded libraries (DELs) have long been established for protein ligand discovery, recent studies have demonstrated their feasibility for identifying RNA-binding small molecules. To further advance RNA-targeted ligand discovery, a diverse, solid-phase DEL enriched in privileged RNA-binding scaffolds was constructed and applied to identify ligands of r(G4C2)exp, a toxic RNA repeat expansion implicated in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). DEL selection outcomes were analyzed through large-scale molecular docking integrated with physicochemical and structure–activity relationship (SAR) analyses. Correlations were observed between docking predictions and experimental enrichment trends, supporting lead identification. The lead compound was subsequently optimized based on rational design, resulting in analogues with enhanced binding affinity and bioactivity. These findings demonstrate that RNA ligand identification can be effectively achieved by combining DNA-encoded library technology with computational approaches for rational design and analysis and highlight a broadly adaptable platform for RNA-targeted small-molecule discovery. Learn More DEL-Related Publications 6 May 2026 Unlocking chemical diversity in aptamers with DNA orthogonal barcodes Daniel Saliba,Eiman A Osman,Abdelrahman Elmanzalawy,Christopher Saab,Son Bui,Serhii Hirka,Shaun Anderson,Violeta Toader,Michael D Dore,Felix J Rizzuto,Donatien de Rochambeau,Maureen McKeague,Hanadi F Sleiman Nature Chemistry DOI: 10.1038/s41557-026-02099-5 Abstract Aptamers are a versatile alternative to antibodies as they are smaller, easier to synthesize and less immunogenic. However, while antibodies are composed of 20 chemically diverse amino acids and are established therapeutics, aptamers are composed of only 4 similar nucleobases, thereby limiting their therapeutic potential. Aptamer chemical modifications are restricted to maintain compatibility with enzymatic selection. Here we introduce aptamer-like encoded oligomers (alenomers), highly chemically modified aptamers that are read and sequenced using a DNA code branching from and corresponding to the target-binding oligomer. We build ~300,000-member DNA-encoded libraries using an automated DNA synthesizer and split-and-pool methods, and screen them for protein binding via next-generation sequencing. In contrast to aptamers, alenomers are not restricted by the need for conservative enzyme-compatible modifications. They can thus explore an almost limitless chemical space, enabling the discovery of highly stable, high-affinity protein-binding aptamers, while offering structural insights into their interactions with target molecules. Learn More
OpenDEL™ - Small Molecule Starting Your Journey to Access the Vast Chemical Space The Kit 57 Libraries ~3.8Bn compounds 10 DEL samples To Access Fully Enumerated Molecules Building Block Structures DNA Codon Sequences Scaffolds Information ✔ No Structure Disclosure Fee ✔ No Compound IP License Fee
OpenDEL™ Screening OpenDEL™ screening is carried out by our team of experienced professionals, proficient in handling over 50 different target types including protein-protein interactions, kinases, enzymes, transcription factors, and RNA targets. Our team typically completes the screening experiments within 1-2 weeks.
OpenDEL™ Sequencing HitGen offers high-quality and gold sequencing service includes. Global Sample Shipment Outstanding Sequencing Quality Lightning-speed Result Delivery Diverse Sequencing Options
OpenDEL™ Hit Proposal Analyzing DEL selection data and choosing the right compounds for follow-up necessitates multidisciplinary expertise encompassing biology, computational science, and chemistry. This includes a deep understanding of the experimental design and mechanisms of action (MOAs) in biology, data processing and analysis in computational science, and aspects of both synthetic and DEL chemistry
OpenDEL™ Off-DNA Synthesis HitGen Chemical Services: Innovation-Driven and Precision-Empowered. We transform your DEL hits into tangible results by delivering the pure, complex structures critical for validating discoveries and accelerating their advancement. Choose Your Path: A. Traditional Chemical Synthesis @ HitGen B. High Throughput Chemical Synthesis @ HitGen